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4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), commonly 
called “N-Bomb,” is a synthetic phenethylamine with psychedelic and entactogenic effects; 
it was available on the Internet both as a legal alternative to lysergic acid diethylamide 
(LSD) and as a surrogate of 3,4-methylenedioxy-methamphetamine (MDMA), but now 
it has been scheduled among controlled substances. 25I-NBOMe acts as full agonist 
on serotonergic 5-HT2A receptors. Users are often unaware of ingesting fake LSD, and 
several cases of intoxication and fatalities have been reported. In humans, overdoses 
of “N-Bomb” can cause tachycardia, hypertension, seizures, and agitation. Preclinical 
studies have not yet widely investigated the rewarding properties and behavioral effects 
of this compound in both sexes. Therefore, by in vivo microdialysis, we evaluated the 
effects of 25I-NBOMe on dopaminergic (DA) and serotonergic (5-HT) transmissions in the 
nucleus accumbens (NAc) shell and core, and the medial prefrontal cortex (mPFC) of male 
and female rats. Moreover, we investigated the effect of 25I-NBOMe on sensorimotor 
modifications as well as body temperature, nociception, and startle/prepulse inhibition 
(PPI). We showed that administration of 25I-NBOMe affects DA transmission in the NAc 
shell in both sexes, although showing different patterns; moreover, this compound causes 
impaired visual responses in both sexes, whereas core temperature is heavily affected in 
females, and the highest dose tested exerts an analgesic effect prominent in male rats. 
Indeed, this drug is able to impair the startle amplitude with the same extent in both sexes 
and inhibits the PPI in male and female rats. Our study fills the gap of knowledge on the 
behavioral effects of 25I-NBOMe and the risks associated with its ingestion; it focuses the 
attention on sex differences that might be useful to understand the trend of consumption 
as well as to recognize and treat intoxication and overdose symptoms.
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INTRODUcTION
The appearance of new psychoactive substances (NPS) is 
changing the trend in drug use worldwide (Orsolini et al., 
2015; Miliano et al., 2016; UNODC, 2016; Corkery et al., 2017; 
Orsolini et al., 2017), which includes also their safely perceived 
purchase on the Internet (Miliano et al., 2018). As a matter of 
fact, in the last decades the classical drugs of abuse are being 
progressively substituted by their “legal synthetic alternatives” 
or simply co-abused with these powerful substances. In 2014, 
phenethylamines were the second most used class of NPS, after 
synthetic cannabinoids (UNODC, 2014; UNODC, 2016), while 
now the trend is moving to synthetic opioids (EMCDDA, 2019). 
These compounds are usually abused for their psychedelic and 
entactogenic effects mainly by people who attend electronic 
dance music, parties at nightclubs, and festivals (Palamar et al., 
2016; Schifano et al., 2016; Palamar et al., 2017) in order to reach 
a “dissociative state” from reality, which unfortunately might lead 
to severe clinical issues (Schifano et al., 2019). Phenethylamines 
are a large family of compounds that are molecular variants of 
the core compounds, i.e., amphetamines, 3,4-methylenedioxy-
methamphetamine (MDMA), etc. (Le Roux et al., 2015). The 
N-benzylmethoxy derivatives of the 2C hallucinogens (i.e., 
2C-I, 2C-B, and 2C-C), commonly called NBOMes (4-Iodo-2,5-
dimethoxy-N-(2-methoxybenzyl)phenethylamine), are probably 
the most famous; they used to be marketed as a legal lysergic acid 
diethylamide (LSD), with aliases such as “Smiles” and “N-bombs.” 
They act as full agonist on human and rat 5-HT2A receptors (Ki = 
0.044 nM and Ki = 0.087 nM, respectively), with high affinity 
(Braden et al., 2006). As a consequence, low doses of the order 
of 50 μg are able to produce psychoactive effects (Kyriakou et al., 
2015; Suzuki et al., 2015). They are usually ingested sublingually, 
orally, by insufflations, rarely intravenously, and it seems to be 
active at doses as low as 50–250 μg, but the typical dose range 
is 500–800 μg (Halberstadt and Geyer, 2014). The duration of 
action depends on the route of administration, ranging from 
4–6 h (insufflation) to 6–10 h (sublingual). According to analysis 
performed in seizures of these products, 25I-NBOMe seems to be 
the most present compound. The central effects of these substances 
are due to the activation of 5-HT2A receptors, which are heavily 
expressed in cortical and forebrain areas, various brainstem 
nuclei, and the hippocampus (Cornea-Hébert et al., 2002), but 
side effects are both central and peripheral. Indeed, overdoses 
of “N-Bomb” can cause several toxicological effects such as 
tachycardia, hypertension, seizures, and agitation persisting for 
up to 3 days (Hill et al., 2013; Kelly et al., 2013; Rose et al., 2013; 
Stellpflug et al., 2014; Hieger et al., 2015). Several intoxication 
cases and some fatalities have been reported after the recreational 
use of 25-NBOMes (Walterscheid et al., 2014; Andreasen et al., 
2015; Laskowski et al., 2015; Kueppers and Cooke, 2015; Shanks 
et al., 2015; Suzuki et al., 2015; Adamowicz et al., 2016; Morini 
et al., 2017). Therefore, all the 2C N-benzyl-methoxy derivatives 
were banned and scheduled as illegal drugs in many countries, 
such as Italy, USA, Canada, Russia, Sweden, and China (https://
www.erowid.org/chemicals/2ci_nbome/2ci_nbome_law.shtml). 
Furthermore, the recurring use of these potent 5-HT2A agonists 
may contribute to develop seizures and the serotonin syndrome 
(Bosak et al., 2013), an excessive serotonergic activation that 
results in specific clinical signs, such as tremor, diarrhea, and 
delirium, neuromuscular rigidity, and hyperthermia in life-
threatening cases (Boyer and Shannon, 2005). Despite the 
widespread use of these compounds, and the effects reported 
in humans, there is a lack of knowledge about their behavioral 
or toxicological effects. The serotonergic psychedelic effects of 
this compound have been confirmed by behavioral responses 
such as head twitch in C57BL/6J mice (NBOMe 0.1–1 mg/kg, 
s.c.) (Halberstadt and Geyer, 2014), wet dog shakes, and back 
muscle contraction (0.01–3 mg/kg, s.c.) in rats (Elmore et al., 
2018), and all these effects were prevented by the administration 
of the selective 5-HT2A antagonist M100907 (Halberstadt and 
Geyer, 2014; Elmore et al., 2018). Indeed, 25I-NBOMe time-
dependently and dose-dependently decreased locomotor activity 
in mice (Eshleman et al., 2014; Gatch et al., 2017) and showed full 
substitution of LSD in rats drug discrimination and more than 
50% of appropriate responding in MDMA-trained rats (Eshleman 
et al., 2014). The MDMA-like action of 25I-NBOMe has been 
also confirmed in vitro since it acts inhibiting the monoamine 
reuptake transporters with different IC50 (hSERT, IC50 = 4.3 µM; 
hDAT, IC50 = 75 µM; hNET, IC50 = 19 µM) in HEK 293 cells 
(Zwartsen et al., 2017). Recently, it has been demonstrated that 
this compound increases dopamine (DA) and serotonin (5-HT) 
in the frontal cortex of male Wistar–Han rats when administered 
at 3 mg/kg subcutaneously (Herian et al., 2019). Moreover, DA 
levels in mice synaptosomal striatal fractions were increased by 
in vitro administration of this substance, and male mice showed 
an increased conditioned place preference when injected with 
25I-NBOMe (0.3 mg/kg, i.p.) (Jeon et al., 2019). Conversely, 
male Sprague–Dawley rats did not press the active lever to obtain 
an infusion of 25I-NBOMe (Jeon et al., 2019). Collectively, the 
results available so far suggest a putative abuse liability of this 
compound, but further investigations on the neurochemical and 
behavioral effects seem to be necessary. Therefore, the aim of this 
study was to evaluate the effect of 25I-NBOMe on DA and 5-HT 
transmissions, performing in vivo microdialysis in three terminal 
areas strongly involved in reward and drug seeking [nucleus 
accumbens (NAc) shell and core and medial prefrontal cortex 
(mPFC)]. Moreover, several behavioral tests were performed to 
assess sensorimotor impairment as well as the risk of developing 
hyperthermia and have an altered nociceptive response under 
the effect of 25I-NBOMe. Additionally, due to the possibility to 
develop drug use-related psychotic disorders, we included an 
analysis of the acoustic startle reflex (prepulse inhibition, PPI) 
that is considered a marker of vulnerability for neuropsychiatric 
disorders (Siegel et al., 2013; Marti et al., 2019). Moreover, sex 
differences in drug addiction behavior have been extensively 
reported in both humans and rodents (Becker et al., 1982; Jackson 
et al., 2006; Zhao and Becker, 2010; Cummings et al., 2014; 
Fattore et al., 2014). The reason of such great differences is due to 
Abbreviations: DA, Dopamine/dopaminergic; DOI, (±)-2,5-Dimethoxy-4- 
iodoamphetamine; HPLC, High-performance liquid chromatography; 
25I-NBOMe, 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine; LSD, 
Lysergic acid diethylamide; MDMA, 3,4-Methylenedioxy-methamphetamine; 
mPFC, Medial prefrontal cortex; NAc, Nucleus accumbens; NPS, Novel 
psychoactive substances; PPI, Prepulse inhibition; 5-HT, Serotonin/serotonergic.
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dimorphisms in the anatomy of the reward brain circuits (Walker 
et al., 2012), differences in the intrinsic properties of DA neurons 
(Melis et al., 2013), as well as ovarian hormone fluctuations 
(Becker and Hu, 2008; Castelli et al., 2014).Considering the lack 
of data about the effects of this compound on females, we decided 
to perform the entire experimental study in both male and female 
rats in order to underline possible sex differences. In addition, 
in order to try to explain why adolescent girls seem to be more 
susceptible at intense negative psychoactive effects of MDMA 
(Liechti et al., 2001), and generally more vulnerable to develop 
hallucinogen dependence (Wu et al., 2009; Wu et al., 2010), in an 
initial stage of the study, we investigate the relationship among 
different estrous cycle phases and extracellular DA and 5-HT 
levels in response to acute 25I-NBOMe administration.
MATeRIAls AND MeThODs
Animals
Male and female Sprague–Dawley rats, weighing 275–300  g 
(Harlan Italy), were used for in vivo microdialysis and 
behavioral tests. Rats were housed four per cage, in standard 
plastic cages with wood chip bedding, at temperature of 22  ± 
2°C and 60% humidity and under a 12-h light/dark cycle 
(lights on from 7.00 a.m.). Tap water and standard laboratory 
rodent chow (Mucedola, Settimo Milanese, Italy) were provided 
ad libitum in the home cage. All animal experiments were 
carried out in accordance with the Guidelines for the Care and 
Use of Mammals in Neuroscience and Behavioral Research 
according to Italian (D.L. 116/92 and 152/06) and European 
Council directives (609/86 and 63/2010) and in compliance 
with the approved animal policies by the Ethical Committee 
for Animal Experiments (CESA, University of Cagliari) and 
the Italian Ministry of Health (Aut. N. 162/2016- PR; Aut. 
N.352/2015-PR). All animals were handled once daily for 5 min 
for five consecutive days before the beginning of the behavioral 
tests. We made all efforts to minimize pain and suffering and to 
reduce the number of animals used.
substances and Doses
25I-NBOMe was purchased from LGC Standards S.r.l. (Milan, 
Italy), dissolved in 2% EtOH, 2% Tween 80, and 96% saline, 
and administered intraperitoneally (3 ml/kg) at different doses. 
A wider range of doses of 25I-NBOMe (0.1, 0.3, 0.5, and 1.0 
mg/kg, i.p.) were chosen for behavioral tests in order to assess 
which was the lower effective dose both in male and female rats. 
The most effective doses (0.3 and 1.0 mg/kg, i.p.) were chosen 
for microdialysis experiments in order to minimize the number 
of rats.
Determination of the estrous cycle 
Phases in Female Rats
Before starting experiments, the estrous cycle of female rats 
was monitored every day for 15 days, collecting vaginal smears 
in the early morning (between 8:00 and 9:00 a.m.). Vaginal 
secretion was collected by flushing into the vagina and out 
(two to three times) 20 µl of saline (NaCl 0.9%). The pipette tip 
was inserted gently and not deeply in order to avoid cervical 
stimulation (Cora et al., 2015). One vaginal fluid drop per rat 
was placed on glass slides. Unstained material was observed 
by bright-field microscopy, with ×20 and ×40 objective lenses 
(Marcondes et al., 2002). Observing the cytology of vaginal 
smear, it is possible to discriminate three cell types, and it is 
well established that the proportion among them corresponds 
to a particular phase of estrous cycle in rodents (Goldman 
et al., 2007; Cora et al., 2015). In this way, we were able to 
determine the following: proestrus (predominant nucleated 
epithelial cells); estrus (anucleuated cornified cells); metestrus 
(leukocytes, cornified, and nucleated epithelial cells in the same 
proportion); and diestrus (predominant little round leukocytes) 
(data not shown).
In Vivo Microdialysis studies
Surgery
Male and female Sprague–Dawley rats (275–300 g; Harlan, Italy) 
were anaesthetized with isoflurane gas and maintained under 
anesthesia using a breathing tube under a scavenging system 
while placed in a stereotaxic apparatus and implanted with 
vertical dialysis probes prepared as previously described (De 
Luca et al., 2015) with 1.5 or 3 mm dialyzing portion for NAc or 
mPFC, respectively. According to the rat brain atlas of Paxinos 
and Watson (1998), animals were implanted in the NAc shell 
(A +2.2, L +1.0 from bregma; V −7.8 from dura) or core (A +1.4, 
L +1.6 from bregma; V−7.6 from dura), or in the mPFC (A +3.7, 
L +0.8 from bregma; V −5.0 from dura).
Analytical Procedure
On the day following surgery, animals were connected to an 
infusion pump and probes were perfused with Ringer’s solution 
(147 mM NaCl, 4 mM KCl, and 2.2 mM CaCl2) at a constant 
rate of 1 µl/min. After a washout of 1 h, dialysate samples (20 µl) 
were collected every 20 min and injected into an HPLC equipped 
with a reversed-phase column (C8 3.5 um, Waters, USA) and a 
colorimetric detector (ESA, Coulochem II; ESA-CDS software) 
to quantify DA and 5-HT. The electrodes of the analytical cell 
were set at +125 mV (oxidation) and −175 mV (reduction) to 
detect dopamine and at −175 mV (oxidation) and +220 mV 
(reduction) to detect serotonin. The mobile phase contained 
50  mM NaH2PO4, 0.1 mM Na2EDTA, 0.5 mM n-octyl sulfate, 
and 15% (v/v) methanol to evaluate dopamine concentration and 
22% (v/v) methanol for serotonin detection (the pH of mobile 
phase was adjusted with Na2HPO4 to 5.5 and 5.7 for dopamine 
and serotonin, respectively). The sensitivity of the assay for 
DA/5-HT was 5 fmol/sample. Basal dialysate were collected 
until DA and 5-HT levels did not differ more than 10% in three 
consecutive samples. The average value was considered as the 
basal levels of DA/5-HT. The animals were treated with saline 
or 25I-NBOMe and monoamine levels were monitored for 2 h 
after the treatment. At the end of the experiment, animals were 
sacrificed and their brains removed and stored in formalin (8%) 
for histological examination to verify the correct placement of 
the microdialysis probe.
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Statistical Analysis of Microdialysis Experiments
All the numerical data are given as mean ± SEM. Data were 
analyzed by utilizing one-way ANOVA or repeated measures 
ANOVA (two-way and three-way). Results from treatments 
showing significant overall changes were subjected to Tukey’s 
tests for post hoc comparisons, with significance at p < 0.05.
Behavioral studies
The differential effects of 25I-NBOMe were investigated using 
a battery of behavioral tests widely used in studies of “safety-
pharmacology” for the preclinical characterization of NPS in rodents 
(De Luca et al., 2015; Vigolo et al., 2015; Ossato et al., 2015; Ossato 
et al., 2016; Canazza et al., 2016; Canazza et al., 2017; Giannotti et al., 
2017; Fantinati et al., 2017; Marti et al., 2019). To reduce the animal’s 
stress induced by manipulation, and to confirm the stability and 
reproducibility over time of the responses of our tests, animals were 
trained two times per week for 2 weeks before the pharmacological 
treatment. All experiments were performed between 8:30 a.m. and 
2:00 p.m. Experiments were conducted in blind by trained observers 
working together in pairs (Ossato et al., 2016). The behavior of rats 
(sensorimotor responses) was videotaped and analyzed off-line by 
a different trained operator that gives test scores. The behavioral 
tests were performed in a consecutive manner using six rats per 
treatment, according to the following sequence: measures of visual 
object responses (frontal and lateral views), overall tactile response 
(pinna, vibrissae, and corneal reflexes), acoustic response, measures 
of core body temperature (rectal measurement), visual placing 
response, and determination of the mechanical (tail pinch) acute 
pain. Despite the repetition of tests during the time, no changes 
in parameters such as body core temperature and responses to 
noxious stimuli, which are sensitive to stressful situations (Adriaan 
Bouwknecht et al., 2007; Kozlov et al., 2015), have been observed 
in naive animals and in saline/vehicle-treated animals. The startle 
and prepulse inhibition studies, instead, were performed on another 
cohort of rats using seven animals per treatment.
Sensorimotor Studies
We studied the voluntary and involuntary sensorimotor 
responses resulting from different rat reactions to visual, acoustic, 
and tactile stimuli (Ossato et al., 2015; Marti et al., 2019).
Evaluation of the Visual Response
Visual response was verified by two behavioral tests, which 
evaluated the ability of the rat to capture visual information 
even when the animal is stationary (the visual object response) 
or when it is moving (the visual placing response). Visual object 
response test was used to assess the ability of the rat to see an object 
approaching from the front or side that causes the animal to move 
or turn the head or withdraw it (Marti et al., 2019). For the frontal 
visual response, a white horizontal bar was moved frontally to the 
rat head and the maneuver was repeated three times. For the lateral 
visual response, a small dentist’s mirror was moved into the rat’s 
field of view in a horizontal arc, until the stimulus was between 
the rat’s eyes. The procedure was conducted bilaterally and was 
repeated three times. The score assigned was a value of 1 if there 
was a reflection in the rat movement or 0 if not. The total value 
was calculated by adding the scores obtained in the frontal with 
that obtained in the lateral visual object response (overall score, 
9). Evaluation of the visual object response was measured at 0, 
5, 30, and 60 min post-injection. Visual placing response test is 
performed using a tail suspension modified apparatus able to bring 
down the rat towards the floor at a constant speed of 10 cm/s (Marti 
et al., 2019). A camera videotapes the downward movement of the 
rat. The analysis frame by frame allows evaluating the beginning 
of the reaction of the rat while it is close to the floor. When the rat 
starts the reaction, an electronic ruler evaluates the perpendicular 
distance in millimeters between the eyes of the rat to the floor. The 
naive rats perceive the floor and it prepares to contact at a distance 
of about 27 ± 4.5 mm. Evaluation of the visual placing response 
was measured at 0, 15, 40, and 70 min post-injection.
Evaluation of Acoustic Response
Acoustic response measures the reflex of the rat in replay to an 
acoustic stimulus produced behind the animal. In particular, 
four acoustic stimuli of different intensities and frequencies were 
tested (Marti et al., 2019). Each sound test was repeated three 
times, giving a value of 1 if there was a response and 0 if not 
present, for a total score of 3 for each sound. The acoustic total 
score was calculated by adding scores obtained in the four tests 
(overall score, 12). Evaluation of the visual object response was 
measured at 0, 10, 30, and 60 min post-injection.
Evaluation of Tactile Response
The overall tactile response in the rat was verified through 
vibrissae, pinna, and corneal reflexes (modified from Ossato 
et al., 2018; Marti et al., 2019). Vibrissae reflex was evaluated by 
touching vibrissae (right and left) with a thin hypodermic needle 
once for side, giving a value of 1 if there was a reflex (turning 
of the head to the side of touch or vibrissae movement) or 0 if 
not present (overall score, 2). Evaluation of the vibrissae reflex 
was measured at 0, 5, 30, and 60 min post-injection. Pinna reflex 
was assessed by touching pavilions (left and right) with a thin 
hypodermic needle. First, the interior pavilions and then the 
external. This test was repeated twice for side, giving a value of 1 if 
there was a reflex and 0 if not present (overall score, 4). Evaluation 
of the pinna reflex was measured at 0, 5, 30, and 60 min post-
injection. Corneal reflex was assessed gently touching the cornea 
of the rat with a thin hypodermic needle and evaluating the 
response, assigning a value of 1 if the rat moved only the head, 2 
if it only closed the eyelid, and 3 if it closed the lid and moved the 
head. The procedure was conducted bilaterally (overall score, 6) 
and was measured at 0, 5, 30, and 60 min post-injection.
Evaluation of Core and Surface Body Temperature
To assess the effects of 25I-NBOMe on thermoregulation, we 
measured both changes in the core (rectal) and surface (ventral 
fur) temperature. The core temperature was evaluated by a probe 
(1-mm diameter) that was gently inserted, after lubrication with 
liquid vaseline, into the rectum of the rat (to about 2 cm) and left 
in position until the stabilization of the temperature (about 10 s; 
Marti et al., 2019). The probe was connected to a Cole Parmer 
digital thermometer, model 8402. The surface temperature was 
measured by a Microlife FR 1DZ1 digital infrared thermometer, 
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placed at 1 cm from the surface of the abdomen of the rat (Marti 
et al., 2019). Core and surface rat body temperatures were 
measured at 0, 10, 35, and 65 min.
Evaluation of Pain Induced by a Mechanical 
Stimulation of Tail
Acute mechanical nociception was evaluated using the tail and 
hind paw pinch tests (modified by (Vigolo et al., 2015). A special 
rigid probe connected to a digital dynamometer (ZP-50N, 
IMADA, Japan) was gently placed on the tail (in the distal 
portion) or the hind paw of the rat and a progressive pressure was 
applied. When the rat flicked its tail or removed the hind paw, 
the pressure was stopped and the digital instrument saved the 
maximum peak of weight supported (g/force). A cutoff (500 g/
force) was set to avoid tissue damage. The test was repeated three 
times and the final value was calculated with the average of three 
obtained scores. Acute mechanical nociception was measured at 
0, 15, 40, and 70 min post-injection.
Startle and Prepulse Inhibition Analysis
Startle and prepulse inhibition studies were performed as 
previously reported (Marti et al., 2019). Male and female rats 
were tested for acoustic startle reactivity in startle chambers (Ugo 
Basile apparatus, Milan, Italy) consisting of a sound-attenuated, 
lighted, and ventilated enclosure holding a transparent non-
restrictive Perspex® cage (modified version for rats 200 × 90 × 80 
mm). A loudspeaker mounted laterally the holder produced all 
acoustic stimuli. Peak and amplitudes of the startle response were 
detected by a load cell. At the onset of the startling stimulus, 300-
ms readings were recorded and the wave amplitude evoked by 
the movement of the rat startle response was measured. Acoustic 
startle test sessions consisted of startle trials (pulse-alone) and 
prepulse trials (prepulse + pulse). The pulse-alone trial consisted 
of a 40-ms 120-dB pulse. Prepulse + pulse trials sequence 
consisted of a 20-ms acoustic prepulse, 80-ms delay, and then a 
40-ms 120-dB startle pulse (100-ms onset–onset). There was an 
average of 15 s (range = 9–21 s) between the trials. Each startle 
session began with a 10-min acclimation period with a 65-dB 
broadband white noise that was present continuously throughout 
the session. The test session contained 40 trials composed by 
pulse-alone and prepulse + pulse trials (with three different 
prepulses of 68, 75, and 85 dB) presented in a pseudorandomized 
order. Male and female rats were placed in the startle chambers 5 
min after treatment with 25I-NBOMe. The entire startle/PPI test 
lasted 20 min. The amount of PPI was expressed as the percentage 
decrease in the amplitude of the startle reactivity caused by the 
presentation of the prepulse (% PPI). 25I-NBOMe (0.1–1 mg/kg, 
i.p.) was administered intraperitoneally and startle/PPI responses 
were recorded 30 min (including the 10-min acclimation period) 
after drug injections.
Statistical Analysis of Behavioral Tests
Core and surface temperature values are expressed as the difference 
between control temperature (before injection) and temperature 
following drug administration (Δ°C). Antinociception (tail pinch 
tests) is calculated as percent of maximal possible effect {EMax% = 
[(test − control latency)/(cut-off time − control)] × 100}. Data are 
expressed in absolute values, Δ°C (core and surface temperature), 
Emax% (tail pinch tests), and arbitrary units (tail rigidity). In 
sensorimotor response experiments, data are expressed in 
arbitrary units (visual objects response, acoustic response, 
vibrissae, corneal, and pinna reflex) and percentage of baseline 
(visual placing response). The statistical analyses of the effects of 
the individual substances in different concentrations over time 
and that of antagonism studies in histograms were performed 
by ANOVA (two-way) followed by Bonferroni’s test for multiple 
comparisons. The statistical analysis was performed with the 
program Prism software (GraphPad Prism, USA). The amount 
of PPI was calculated as a percentage score for each prepulse + 
pulse trial type: %PPI = 100 − {[(startle response for prepulse + 
pulse trial)/(startle response for pulse-alone trial)] × 100}. Startle 
magnitude was calculated as the average response to all pulse-
alone trials. All the numerical data are given as mean ± SEM. 
Data were analyzed by utilizing repeated measures ANOVA. 
The statistical analysis was performed with the program Prism 
software (GraphPad Prism, USA).
ResUlTs
evaluation of estrous cycle
Initially, we evaluated the estrous cycle phase prior to the 
microdialysis experiment, as described in Materials and Methods. 
Three-way ANOVA was performed comparing proestrus–estrus 
phase with metestrus–diestrus, and no significant differences 
have been observed. For this reason, we decided to not show 
those data and combine the female data across the estrous cycle 
for simplicity.
Dopamine and serotonin Basal levels
Rat basal values of DA, expressed as fmol/20 μl sample (mean ± 
SEM), were in males: NAc shell 48 ± 9 (N = 7), NAc core 50 ± 
13 (N = 5), mPFC 19 ± 3 (N = 8); in females: NAc shell 53 ± 6 
(N = 23), NAc core 56 ± 4 (N = 18), mPFC 22 ± 2 (N = 19) (see 
Figures 1A). Rat basal values of 5-HT, expressed as fmol/20 μl 
sample (mean ± SEM), were in males: NAc shell 10 ± 1 (N = 11), 
NAc core 8 ± 2 (N = 8), mPFC 12 ± 4 (N = 10); in females: NAc 
shell 15 ± 2 (n = 23), NAc core 17 ± 3 (n = 18), mPFC 18 ± 3 (n = 
21) (see Figure 1B). One-way ANOVA was performed for each 
terminal area, revealing no sex differences in both DA and 5-HT 
basal outputs (as shown in Figures 1A, B).
effect of 25I-NBOMe Administration on DA 
Transmission in the NAc shell and core 
and in the mPFc
Males
In this experiment, we evaluated the effect of two doses of 
25I-NBOMe (0.3 and 1.0 mg/kg, i.p.) on extracellular DA levels in 
NAc shell and core and the mPFC (Figures 2A–C). As shown in 
Figure 2, this phenethylamine affects DA transmission to a small 
extent only in NAc shell and core, but not in mPFC in male rats. 
Three-way ANOVA showed a main effect of treatment (F2,30 = 6.50, 
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*p < 0.05) and time × area interaction (F12,180 = 2.18, *p < 0.05). 
In animals implanted in NAc shell, two-way ANOVA showed a 
main effect of treatment (F2,12 = 7.79, *p < 0.01) and time (F6,72 = 
3.62,*p < 0.01). Tukey’s post hoc tests showed a larger increase of 
dialysate DA in the NAc shell after 25I-NBOMe 0.3 mg/kg, i.p., 
revealing differences at the 20-min sample with respect to basal 
values (Figure 2A). In animals implanted in NAc core, two-way 
ANOVA showed a main effect of time (F6,12 = 3.10, *p < 0.05). 
Tukey’s post hoc tests showed a larger increase of dialysate DA in the 
NAc core, revealing differences at the 40-min sample with respect 
to basal values (Figure 2B). In animals implanted in mPFC, two-
way ANOVA showed no significant effects (Figure 2C).
Females
In this experiment, we evaluated the effect of two doses of 
25I-NBOMe (0.3 and 1.0 mg/kg, i.p.) on extracellular DA levels 
in NAc shell and core and the mPFC (Figures 2D–F). The 
dopamine transmission is affected by the administration of the 
drug in the NAc shell and lightly in the mPFC, but not in the 
NAc core. Three-way ANOVA showed a main effect of treatment 
(F2,83 = 10.33, *p < 0.0001), time (F6,498 = 6.63, *p < 0.0001), time × 
area interaction (F12,498 = 2.55, *p < 0.005), and time × treatment 
interaction (F12,498 = 3.08, *p < 0.0005). In animals implanted in 
NAc shell, two-way ANOVA showed a main effect of treatment 
(F2,31 = 3.65, *p < 0.05), and time × treatment interaction (F12,186 = 
2.47, *p < 0.01). Tukey’s post hoc tests showed a larger increase of 
dialysate DA in the NAc 16 shell after 25I-NBOMe 0.3 mg/kg, i.p., 
revealing differences at the at the 40-, 60-, and 120-min samples 
with respect to basal values (Figure 2D). In animals implanted 
in NAc core, two-way ANOVA showed no effects (Figure 2E). In 
animals implanted in mPFC, two-way ANOVA showed a main 
effect of treatment (F1,124 = 4.17, *p < 0.05) and time (F6,144 = 
5.49, *p < 0.0001). Tukey’s post hoc test showed a larger increase 
of dialysate DA in the mPFC after 25I-NBOMe 0.3 mg/kg, i.p., 
revealing differences at the 40-min samples with respect to basal 
values (Figure 2F).
In an attempt to compare the effects observed in male 
and female rats, a four-way ANOVA has been performed. No 
statistically significant differences between sexes have been shown.
effect of 25I-NBOMe Administration on 
5-hT Transmission in the NAc shell and 
core and in the mPFc
Males
In this experiment, we evaluated the effect of two doses of 
25I-NBOMe (0.3 and 1.0 mg/kg, i.p.) on extracellular 5-HT levels 
in NAc shell and core and in the mPFC. As shown in Figures 
2G–I, the compound did not affect the serotonergic transmission 
in all the areas studied. Three-way ANOVA showed a significant 
time × treatment interaction (F12,156 = 1.89, *p < 0.05). Two-
way ANOVA analysis did not highlight significative differences 
between vehicle-treated animals and 25I-NBOMe-treated 
animals either for the three areas.
Females
In this experiment, we evaluated the effect of 25I-NBOMe (0.3 
and 1.0 mg/kg, i.p.) on extracellular 5-HT levels in NAc shell, NAc 
core, and mPFC. As shown in Figures 2J–L, the compound affects 
the serotonergic transmission to a small extent only in NAc shell. 
Three-way ANOVA showed a main effect of area (F2,75 = 14.28, 
*p < 0.05), treatment (F2,75 = 4.58, *p < 0.05), and area × treatment 
interaction (F42,75 = 4.9, *p < 0.005). Tukey’s post hoc tests showed 
no differences. In animals implanted in NAc shell (Figure 2J), 
two-way ANOVA showed a main effect of treatment (F2,35 = 15.24, 
*p < 0.0001) and time (F6,210 = 3.12, *p < 0.01), but no significant 
differences were revealed by Tukey’s post hoc test. Two-way 
ANOVA analysis did not highlight significant differences between 
vehicle-treated animals and 25I-NBOMe-treated animals for the 
NAc core (Figure 2K). In animals implanted in the mPFC (Figure 
2L), two-way ANOVA showed a main effect of treatment (F2,23 = 
3.48, *p < 0,05), without any significant results in the Tukey’s post 
hoc test. In an attempt to compare the effects observed in male 
and female rats, a four-way ANOVA has been performed. No 
statistically significant differences between sexes have been shown.
effects of 25I-NBOMe on Behavioral Tests
Sensorimotor Studies
Evaluation of the Visual Object Response
Visual object response did not change in both vehicle-treated male 
and female rats over 60 minutes Of observation (Figures 3A, B). 
Systemic administration of 25I-NBOMe (0.1–1 mg/kg, i.p.) reduced 
FIgURe 1 | Rat dopamine (A) and serotonin (B) basal levels in both male 
(blue bars) and female (magenta bars) rats. Results are expressed as 
the mean ± SEM of change in DA/5-HT extracellular levels expressed as 
fmol/20 μl sample in nucleus accumbens (NAc) shell, NAc core, and mPFC.
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FIgURe 2 | Continued
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FIgURe 2 | Effect of 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) administration (0.3 and 1.0 mg/kg, i.p) on dopamine (DA) (A–F) 
and serotonin (5-HT) (g–l) transmissions in the nucleus accumbens (NAc) shell, NAc core, and medial prefrontal cortex (mPFC) in male (blue symbols) and female 
(magenta symbols) rats. Results are expressed as the mean ± SEM of change in DA/5-HT extracellular levels expressed as the percentage of basal values. The 
arrow indicates the start of i.p. injection at of vehicle (circles) or 25I-NBOMe 0.3 mg/kg (triangles) or 25I-NBOMe 1.0 mg/kg (squares) in NAc shell, NAc core, and 
mPFC. Statistical analysis was performed by three-way or two-way ANOVA followed by the Tukey’s HSD post hoc test for multiple comparisons. Solid symbol:  
p < 0.05 with respect to basal values (DA males: NAc shell, N = 15; NAc core, N = 10; mPFC, N = 14; DA females: NAc shell, N = 34; NAc core, N = 31; mPFC,  
N = 27; 5-HT males: NAc shell, N = 11; NAc core, N = 10; mPFC, N = 11; 5-HT females: NAc shell, N = 38; NAc core, N = 20; mPFC, N = 26).
FIgURe 3 | Intraperitoneal injection (0.1–1 mg/kg) of 25I-NBOMe in male and female rats on the visual object test (A and B), on the acoustic response (c and D), 
and on the visual placing test (e and F). Data are expressed as arbitrary units (A, B, c, and D) or percentage of basal (e and F) and represent the mean ± SEM of 
six determinations for each treatment. Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s test for multiple comparisons for the dose–
response curve at different times. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle.
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the visual object response in both sex rats and the effect persisted 
up to 60 min (Figures 3A, B). Two-way ANOVA followed by the 
Bonferroni’s test for multiple comparisons in male rats showed 
a significant effect of treatment (F4,140 = 22.24, p < 0.0001), time 
(F3,140  = 22.47, p < 0.0001), and time × treatment interaction 
(F12,140 = 4.478, p < 0.0001). The same statistical analysis for female 
rats showed a significant effect of treatment (F4,140 = 8.207, p < 
0.0001), time (F3,140 = 15.79, p < 0.0001), and time × treatment 
interaction (F12,140 = 2.149, p < 0.05).
Evaluation of the Acoustic Response
Acoustic response did not change in both vehicle-treated male and 
female rats over 60 min of observation (Figures 3C, D). Systemic 
administration of 25I-NBOMe impairs the acoustic response only 
in male rats at the two highest doses tested, 0.5 and 1 mg/kg, and 
this effect is persistent up to 60 min after the treatment (Figure 
3C). Two-way ANOVA for male rats showed a significant effect 
of treatment (F4,140 = 14.54, p < 0.0001), time (F3,140 = 9.144, p < 
0.0001), and time × treatment interaction (F12,140 = 2.061, p  < 
0.05). The acoustic response was not inhibited in female rats by 
25I-NBOMe. Two-way analysis showed a significant effect of 
time (F3,140 = 3.694, p < 0.05), and Bonferroni’s test for multiple 
comparisons showed a tardive little effect displayed by the dose of 
0.5 mg/kg, i.p., at 60 min (Figure 3C, D).
Evaluation of the Visual Placing Response
Visual placing response slightly decreased in both vehicle-
treated male and female rats over 70 min of observation (~17% 
of reduction at 70 min; Figures 3E, F). Systemic administration 
of 25I-NBOMe reduced the visual placing response in both rat 
sexes at all the doses tested (0.1–1 mg/kg, i.p.) and the effect 
persisted up to 70 min, as shown in Figure 3E. Two-way 
analysis showed a significant effect of treatment (F4,140 = 17.25, 
p < 0.0001), time (F3,140 = 31.63, p < 0.0001), and time × 
treatment interaction (F12,140 = 2.582, p < 0.005) for male rats. 
For female rat, as shown in Figure 3F statistical analysis showed 
a significant effect of treatment (F4,140 = 16.23, p < 0.0001), time 
(F3,140 = 39.89, p < 0.0001), and time × treatment interaction 
(F12,140 = 2.135, p < 0.05).
Evaluation of the Tactile Response
Overall tactile responses did not change in both vehicle-treated 
male and female rats over 65 min of observation (Figures 4A, B). 
As shown in Figure 4A, intraperitoneal injection (0.1–1 mg/kg) 
of 25I-NBOMe affected male tactile responses with a significant 
effect of treatment (F4,140 = 8.942, p < 0.0001) and time (F3,140 = 
4.916, p < 0.05). No effects on females’ tactile responses were 
observed (Figure 4B).
Evaluation of Core and Surface Body Temperature
Core body temperature did not change in both vehicle-treated 
male and female rats over 65 min of observation (Figures 4C, D). 
Systemic administration of 25I-NBOMe (0.1–1 mg/kg, i.p.) 
did not affect core (Figure 4C) body temperatures in male 
rats. Two-way ANOVA showed a significant effect of treatment 
(F4,105 = 8.880, p < 0.0001). The dose of 0.5 mg/kg, i.p., affected 
significantly the core temperature in female rats (Figure 4D), 
with a significant effect of treatment (F4,105 = 12.07, p < 0.0001). 
25I-NBOMe did not affect the surface temperature in male rats; 
neither in females (data not shown).
Evaluation of Pain Induced by a Mechanical Stimulus
The threshold to acute mechanical pain stimulus did not change 
in both vehicle-treated male and female rats over 70 min of 
observation (Figures 4E, F). Systemic administration of the 
highest dose of 25I-NBOMe (1 mg/kg, i.p.) heavily increased 
the threshold to acute mechanical pain stimulus in male rats in 
the tail pinch test [significant effect of treatment (F4,105 = 9.822, 
p < 0.001) and time (F2,105 = 3.110, p < 0.05] (Figure 4E), whereas 
in female rats there is a lower effect with the same dose (Figure 
4F). Statistical analysis showed a significant effect of treatment 
(F4,105 = 4.988, p < 0.001).
Startle/Prepulse Inhibition Studies
Vehicle injection did not change startle/PPI response in male 
and female rats, and the effect was similar in naive untreated 
animals (data not shown). Administration of 25I-NBOMe 
(0.1–1 mg/kg, i.p.) inhibited the PPI in male rats at 68 dB 
(F4,30 = 6.072, p < 0.001) and 75 dB (F4,30 = 7.266, p < 0.001) 
of prepulse intensity (Figure 5A), while it inhibited the PPI 
in female rats at 68 dB (F4,30 = 7.046, p < 0.001), 75 dB (F4,30 = 
6.635, p < 0.001), and 85 dB (F4,30 = 3.501, p < 0.05) of prepulse 
intensity (Figure 5B). Moreover, 25I-NBOMe impaired the 
startle amplitude in male (about ~50% inhibition; F4,30 = 5.98, 
p < 0.05) and female (about ~50% inhibition; F4,30 = 13.07, p < 
0.0001) rats at 1 mg/kg at 30 min after drug administration 
(Figure 5C).
DIscUssION
The psychedelic compound 25I-NBOMe belongs to the 
phenethylamines that are a class of NPS spread among youth, 
with greater diffusion in girls than in boys (Wu et al., 2010; 
UNODC, 2016). 25I-NBOMe is a 5-HT2A receptor agonist 
used as a legal substitute of LSD and to mimic the effect of 
methamphetamine as well (Le Roux et al., 2015; Palamar et 
al., 2016). In this preclinical study, we evaluated the dopamine 
(DA) and serotonin (5-HT) releasing properties and the 
behavioral effects of 25I-NBOMe. Our results showed that 
25I-NBOMe affects the DA transmission in the shell of the NAc 
in both sexes, while the higher variability on the serotonergic 
transmission’s response, compared to DArgic response, leads 
to a lack of significative effect when analyzed by three- or 
two-way ANOVA. However, behavioral data showed that this 
compound causes visual alterations in both sexes, whereas core 
temperature is heavily affected in females, and the highest dose 
tested exerts an analgesic effect particularly prominent in male 
rats. Moreover, it impairs the startle amplitude and inhibits the 
PPI in both sexes.
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25I-NBOMe Affects the Dopaminergic 
Transmission in the NAc shell of Both sexes
It is well established that variability of the basal output may affect 
the extent of increasing or decreasing in neurotransmitters in 
brain areas (Di Chiara, (1990); De Luca et al., 2018). Therefore, 
we started comparing DA and 5-HT basal outputs in male and 
female rats, and we did not observe any differences in any of the 
brain areas studied (i.e., NAc shell and core and the mPFC), in 
agreement with previous microdialysis studies aimed at CPu of 
male and female groups (Xiao and Becker, 1994). Oppositely, 
Lazenka et al. (2017) observed a lower baseline NAc DA 
levels in female compared to male rats. Results obtained by 
monitoring estrous cycle in female rats suggested that, although 
the treatment affected significantly the DA transmission in all 
FIgURe 4 | Intraperitoneal injection (0.1–1 mg/kg) of 25I-NBOMe in male and female rats on the overall tactile responses (A and B) and on core temperature  
(c and D) and tail pinch test (e and F). Data are expressed as arbitrary units (A and B), as difference between control temperature (before injection) and 
temperature following drug administration (Δ°C; see Material and Methods) (B and c), or as percentage of maximum effect (Emax%; (see Material and Methods)  
(e and F) and represent the mean ± SEM of six animals for each treatment. Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s test for 
multiple comparisons for the dose–response curve of each compound at different times. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle.
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the areas studied and the 5-HT transmission in the NAc shell, 
estrous cycle phases are not effective in changing the effects 
of 25I-NBOMe, at least in the present set of experiments. 
Therefore, we combined the female data across the estrous cycle. 
Our in vivo microdialysis studies showed that the lowest dose of 
25I-NBOMe tested (0.3 mg/kg, i.p.) affects the DA transmission 
in male rats in the NAc shell, with a maximal peak of 36% over 
basal value, 20 min after the injection, in the NAc core, with 
an extent of 27% at the 40-min sample, whereas it has no effect 
on the mPFC DA transmission (both doses). No effect has been 
observed in the 5-HT transmission in all the three areas tested, 
with both doses in male rats. The dose of 0.3 mg/kg, i.p., was 
active in female rats as well, increasing both DA and 5-HT 
dialysates in the NAc shell, with a maximal peak of 30% over 
basal value 40 min after the administration, and this effect lasted 
more than 2 h after the drug administration, whereas in the 
mPFC only DA extracellular levels are increased with an extent 
of 45%, and the highest dose of 1.0 mg/kg, i.p., did not show any 
effect in female rats. It is well known that all the drugs of abuse 
exert their rewarding effect increasing the DA transmission 
preferentially in the shell of NAc (Di Chiara et al., 2004; De Luca 
et al., 2015). Therefore, these results suggest that this compound 
has a common and alarming feature with them. These results 
are in line with previous studies showing an increased ex vivo 
striatal DA levels (Jeon et al., 2019) as well as an increased DA 
transmission in cortical areas of male rats (Herian et al., 2019). 
Moreover, 25I-NBOMe seems to act differently on DA and 
5-HT levels in male and female rats, highlighting sex differences 
that might influence the frequency of ingestion, as well as the 
psychoactive effects and the long-term effects. Notably, the 
higher dose tested was not effective in increasing the DA level; 
this effect can be due to the formation of active metabolites 
acting as 5-HT2A antagonists, or it can be the result of off-target 
effects on other receptors, as previously suggested for other NPS 
classes (e.g., synthetic cannabinoids) (De Luca et al., 2016). Sex 
differences have been reported in the initiation of drug use, 
affecting the continuation of drug use as well as the phases of 
abstinence and relapse (Becker and Hu, 2008; Fattore et al., 
2010), but also in the codification of reinforcement and related 
cues (Zlebnik, 2019). The greater increase of DA extracellular 
levels in females compared to males is consistent with previous 
studies reporting that amphetamine (Virdee et al., 2014), 
cocaine (Holly et al., 2012), and MDMA (Lazenka et al., 2017) 
are more effective in increasing DA release in the NAc of female 
rats. The reason for these neurochemical sex discrepancies has 
been historically ascribed to deep biological differences, such as FIgURe 5 | Continued
FIgURe 5 | Effect of the systemic administration of 25I-NBOMe (0.1–1 mg/
kg, i.p.) on prepulse inhibition (PPI) in male (A) and female (B) rats and on 
startle amplitude for both sexes (c). Effects on PPI are shown for the three 
prepulse intensities (68, 75, and 85 dB) 30 min after treatment (A and B). 
Data are expressed (see Material and Methods) as percentage decrease in 
the amplitude of the startle reactivity caused by presentation of the prepulse 
(% PPI) (A and B) and absolute values (in dB) (c). Values represent the 
mean ± SEM of seven animals for each treatment. Statistical analysis was 
performed by one-way ANOVA followed by Bonferroni’s test for multiple 
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle.
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sex dimorphisms in the anatomy of DArgic systems in areas like 
SN and VTA (Walker et al., 2012), as well as ovarian hormone 
fluctuations (Becker and Hu, 2008). Furthermore, other factors, 
as pharmacokinetic (Fonsart et al., 2009), pharmacodynamic, 
and sociocultural differences, have been proposed to take part in 
the propensity to addiction (Franconi et al., 2013). Additionally, 
it has been widely demonstrated that female rats exhibit greater 
sensitivity to psychostimulants compared to males (Walker 
et al., 2012), with several experimental paradigms such as self-
administration and conditioned place preference (Savageau 
and Beatty, 1981; Becker et al., 1982; Lynch and Carroll, 1999; 
Walker et al., 2000; Russo et al., 2003; Roth and Carroll, 2004; 
Harrod et al., 2005; Kantak et al., 2007). Even if we did not 
observe differences in each stage of the estrous cycle, further 
investigations are necessary to examine in depth the role of 
hormones in mediating the effects of this compound. These 
differences among males and females in responding to these 
synthetic compounds could explain recent surveys reporting 
that adolescent girls are more likely, compared to boys, to be 
ecstasy and/or other hallucinogen users (Wu et al., 2010). In 
addition, it has also been reported that a given dose of MDMA 
tends to produce more intense negative psychoactive effects 
in women than in men (Liechti et al., 2001) and that girls may 
generally be more vulnerable than boys to developing symptoms 
of hallucinogen dependence (Wu et al., 2009).
25I-NBOMe causes Visual Alterations in 
Both sexes
Data obtained showed that this compound decreases visual 
responses, causing dangerous visual alterations in both sexes. 
Sensorimotor alterations, especially visual ones, may be due to 
the pro-hallucinogenic action of 25I-NBOMe (Halberstadt and 
Geyer, 2014) and as typically reported for other 5-HT2A agonists 
(Canal and Morgan, 2012; Halberstadt and Geyer, 2013). All 
such hallucinogenic compounds exhibit high affinity for 5-HT2A 
receptors (Roth et al., 1998; González-Maeso and Sealfon, 2009). 
In fact, genetic or pharmacological inactivation of 5-HT2A 
receptor signaling blocks the behavioral effects of hallucinogenic 
compounds in a variety of species, including mice, rats, and 
humans (Fiorella et al., 1995; Vollenweider et al., 1998; González-
Maeso et al., 2003; González-Maeso et al., 2007). Taken together, 
these findings indicate that 25I-NBOMe, by activating 5-HT2A 
receptor in cortico-visual circuits, could impair sensorimotor 
responses by promoting a hallucinogenic state.
25I-NBOMe effects on the Acoustic and 
Tactile Responses
The decrease in the acoustic response is consistent with previous 
studies demonstrating that the administration of the analogue 
(±)-2,5-Dimethoxy-4- iodoamphetamine (DOI), in the dose 
range of 0.25–1.0 mg/kg, disrupted the startle response in 
Sprague–Dawley rats (Swerdlow et al., 2006). Recently, it has been 
demonstrated the role of 5-HT in modulating auditory brainstem 
responses in mice, starting from the cochlear nucleus (Papesh 
and Hurley, 2016); indeed, in the dorsal region of this nucleus, 
the activation of 5-HT2 receptors acts increasing the electrical 
activity of neurons, leading to a final suppression of auditory 
process (Felix et al., 2017; Tang and Trussell, 2017). Moreover, 
it has been recently shown that MDMA reduces acoustic and 
tactile responses as well (Marti et al., 2019), and this is a 5-HT2 
receptor-mediated effect (Geyer and Tapson, 1988).
25I-NBOMe effects on Body Temperature
Hyperthermia, which is one of the symptoms of the serotonin 
syndrome, was observed only in females with the dose 
of 0.5 mg/kg. This difference can be related to a distinct 
pharmacokinetic and pharmacodynamic compared to males, 
as previously described for other substances, which included 
amphetamine (Brady and Randall, 1999; Becker et al., 2001; 
Lynch et al., 2002; Carroll et al., 2004). Importantly, these 
results could explain why MDMA and hallucinogens seem to 
be more effective in women compared to men (Liechti et al., 
2001; Wu et al., 2010).
25I-NBOMe has a greater Analgesic  
in Males
The highest dose tested (1 mg/kg, i.p.) exerts an analgesic effect 
prominent in male rats and minor in female rats, increasing 
the threshold to acute mechanical pain stimulus. This effect in 
male rats is higher than the effect obtained with compounds 
acting by the cannabinoid pathway (De Luca et al., 2015; Vigolo 
et al., 2015). This compound has a great affinity for rat 5-HT2A 
receptors (Ki = 0.087 nM) (Braden et al., 2006), but it has lower 
affinity also for µ-opioid receptors (Ki = 82 nM) and Ki greater 
than 500 nM for 5-HT1A receptors (Nichols et al., 2008). 
Therefore, it is possible to assume that the highest dose tested 
binds 5-HT2A receptors first, and further with other receptors 
such as 5-HT1A and µ-receptors, producing the analgesic effect. 
It is well known that serotonergic pathways running from the 
brainstem to the spinal cord are considered to be essential to 
the mechanisms of descending pain controls (Mayer et al., 
1971; Zemlan et al., 1980; Clatworthy et al., 1988; Fields et al., 
1991), and 5-HT2A receptors appear to play a critical role on 
nociceptive responses (Bardin et  al., 2000; Sasaki et al., 2001; 
Kjørsvik et al., 2001). In particular, the administration of 
5-HT2A receptor agonist DOI mediates antinociceptive effects 
in the craniofacial nociception (Okamoto et al., 2007). Different 
nociceptive responses have been observed before (Gamaro 
et al., 2014), and they are probably due to sex dimorphism in the 
localization of serotonergic receptors (Araldi et al., 2017), as well 
as different microglia activation within the periaqueductal gray 
(Doyle et al., 2017). Indeed, the activation of 5-HT2A receptors 
has been demonstrated to stimulate the secretion of various 
hormones (Van de Kar et al., 2001), among these the estradiol in 
both animals and humans (Moses et al., 2000; Kugaya et al., 2003; 
Frokjaer et al., 2010; Moses-Kolko et al., 2011). It is well known 
that estradiol is able to increase mechanical pain threshold in 
both sexes (Lu et al., 2012) while estriol fails it. The reason for 
this could be the ability of females to metabolize estradiol in 
estriol more quickly than males.
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25I-NBOMe Impairs the Acoustic startle 
Reflex in Male and Female Rats
Notably, 25I-NBOMe in our experiments showed to impair 
the acoustic startle reflex with the same extent (about 50% 
inhibition) in both sexes at the highest dose of 1 mg/kg, i.p., 
and to disrupt the sensorimotor gating significantly in both 
male and females compared to the vehicle-treated group 
(dose, 0.3–1 mg/kg, i.p.), with a tendency to an increased 
impairment at the prepulse intensity of 85 dB in females 
compared to males. It has been shown before that LSD exerts 
the same effects on PPI by activating 5-HT2A receptors in 
rats (Halberstadt and Geyer, 2010), and MDMA as well in 
both rats and mice (Marti et al., 2019). These results are 
alarming since the PPI has been widely defined as a marker 
of vulnerability to develop a neuropsychiatric disorder (Marti 
et al., 2019).
cONclUsIONs
In conclusion, we have shown that the synthetic hallucinogen 
25I-NBOMe affects the DArgic transmission in the NAc shell 
in a sex-independent manner, while mPFC DA seems to be 
more responsive in females compared to males. However, 
behavioral data proved that the severity of side effects 
occurring after 25I-NBOMe ingestion, probably mediated 
by serotonin pathways, can be different in male and female 
rats, as suggested also by a tendency, although not statistically 
significant, to a preferential increase of extracellular 5-HT 
in the NAc shell and a long-lasting stimulation in the mPFC 
of females compared to males. Regrettably, the experimental 
conditions of the present study have not been adequate to 
correlate either basal or 25I-NBOMe-stimulated brain levels 
of DA and 5-HT with hormonal fluctuations. In order to 
expand our knowledge on sex differences in the response to 
NPS, further experiments, most likely based on the direct 
evaluation of blood levels of hormones instead of indirect 
estimation by vaginal smears, would be needed. On the 
other hand, the observation of a higher core temperature 
in female rats and a marked analgesic effect in male rats 
after the administration of 25I-NBOMe may account for a 
gender-specific toxicity, thus highlighting possible distinct 
pharmacokinetics and pharmacodynamics as well as impact 
of enzyme genotype among sexes. These features suggest that 
the habit of consuming the psychedelic agent 25I-NBOMe and 
its analogues (Gee et al., 2016) pose a high risk of developing 
hyperthermia (i.e., serotonin syndrome) and has altered 
nociceptive responses. Moreover, the decreased acoustic reflex 
and the impaired visual responses observed in this preclinical 
study, coupled with the unawareness of what is going to be 
ingested in humans, pose a significant issue for public health 
and safety. Notably, in 2016, over 10 million people have been 
reported to drive under the influence of illicit drugs (DUID) 
(Substance Abuse and Mental Health Services Administration, 
2017), and the impairment of visual and acoustic reflexes may 
clearly lead to fatal DUID, as reported after the ingestion of 
NBOMes (Rajotte et al., 2017). Although the findings of the 
present research give us important preclinical information, 
further investigations are necessary to clarify sex differences 
in toxicological responses to different drugs. Moreover, 
studies including pharmacological, toxicological, and forensic 
evidence at both preclinical and clinical levels are needed in 
order to more widely profile NPS effects and intoxication.
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